Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
0 hedge funds and large institutions have $0 invested in Array Biopharma Inc in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $4.08K → $0 (-$4.08K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| 1 |
BAM
Byrne Asset Management
Kingston,
New Jersey
|
-$4.08K |
ARRY Hedge Fund Activity: Q4 2025 in Review
0 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q4 2025, worth a combined $0 — down 100% from $4.08K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ARRY and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Byrne Asset Management, exiting entirely with an estimated $4.08K sold.
- 0 institutional investors held Array Biopharma Inc (ARRY) as of Q4 2025, down from 1 in Q3 2025.
- Funds reported $0 of Array Biopharma Inc stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new Array Biopharma Inc positions in Q4 2025 and 1 closed out, a net change of -1 holder.
- The largest Array Biopharma Inc seller in Q4 2025 was Byrne Asset Management, an estimated $4.08K sold.
Based on aggregated 13F filings for Q4 2025.